期刊文献+

磁共振影像技术在心脏淀粉样变性中的应用 被引量:1

Magnetic resonance imagin in patients with cardiac amyloidosis
下载PDF
导出
摘要 系统性淀粉样变性是一组异质性疾病,其共同的特征是不同来源的错误折叠蛋白质沉积在全身多个组织器官.心脏是常见受累器官之一,心脏淀粉样变性的严重程度是影响患者预后的决定性因素.磁共振技术因具有出色的空间分辨率和高组织对比度,在心脏淀粉样变性的形态学评估、诊断、危险分层和预后评估等方面具有极为广阔的应用前景.本文就磁共振相关技术在心脏淀粉样变性中的应用进展作一综述. Systemic amyloidosis is a group of heterogeneous disorders, Its common feature is the deposition of misfolded proteins from different sources in multiple tissues and organs throughout the body.When the heart is involved, it is called cardiac amyloidosis, and its severity is a decisive factor in patient’s prognosis.Because of its excellent spatial resolution and high tissue contrast, magnetic resonance imaging has a broad application prospect in morphological assessment, diagnosis, risk stratification and prognosis assessment of cardiac amyloidosis.In this article, application progress of nuclear magnetic resonance in cardiac amyloidosis is reviewed.
作者 缪福佳 黄湘华 MIAO Fujia;HUANG Xianghua(National Clinical Research Center of Kidney Diseases,Nanjing University School of Medicine,Jinling Hospital,Nanjing210016,China)
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2021年第2期154-158,共5页 Chinese Journal of Nephrology,Dialysis & Transplantation
基金 江苏省重点研发计划社会发展面上项目(BE2017721)。
关键词 心脏淀粉样变性 心脏磁共振 磁共振成像 cardiac amyloidosis cardiac magnetic resonance magnetic resonance imaging
  • 相关文献

参考文献1

二级参考文献19

  • 1Cohen AD, Comenzo RL. Systemic light-chain amyloidosis : advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program ,2010,2010:287 - 294.
  • 2Gertz MA, Lacy MQ, Dispenzieri A, et al. Amyloidosis. Best Pract Res Clin Haemato1,2005,18 (4) :709 - 727.
  • 3Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med,2003,349(6) :583 -596.
  • 4Kastritis E, Dimopoulos MA. Prognosis and risk assessment in AL amyloidosis—state of the art. Amyloid ,2011,18 ( Suppl 1 ) : 84 - 86.
  • 5Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation ,2005,112 ( 13 ) :2047 - 2060.
  • 6Palladini G,Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction inAL amyloidosis. Circulation ,2003,107 ( 19 ) :2440 - 2445.
  • 7Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet,2003,361 (9371) :1787 - 1789.
  • 8Merlini G,Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol,2011,29(14) :1924 -1933.
  • 9Bergesio F, Ciciani AM, Manganaro M, et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant,2008,23 ( 3 ) :941 - 951.
  • 10Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem,2005,51 ( 5 ) : 878 - 881.

共引文献18

同被引文献1

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部